Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection
Copyright © 2023 Elsevier Ltd. All rights reserved..
A 48-year-old man with poorly controlled HIV presented with severe human monkeypox virus (hMPXV) infection, having completed 2 weeks of tecovirimat at another hospital. He had painful, ulcerating skin lesions on most of his body and oropharyngeal cavity, with subsequent Ludwig's angina requiring repeated surgical interventions. Despite commencing a second, prolonged course of tecovirimat, he did not objectively improve, and new lesions were still noted at day 24. Discussion at the UK National Health Service England High Consequence Infectious Diseases Network recommended the use of 3% topical and then intravenous cidofovir, which was given at 5 mg/kg; the patient made a noticeable improvement after the first intravenous dose. He received further intravenous doses at 7 days and 21 days after the dose and was discharged at day 52. Cidofovir is not licensed for use in treatment of hMPXV infection. Data for cidofovir use in hMPXV are restricted to studies in animals. Four other documented cases of cidofovir use against hMPXV have been reported in the USA in 2022, but we present its first use in the UK. The scarcity of studies into the use of cidofovir in this condition clearly shows the need for robust studies to assess efficacy, optimum dosage, timing, and route of administration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 23(2023), 6 vom: 10. Juni, Seite e218-e226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stafford, Adam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8J337D1HZY |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(23)00044-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352833181 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352833181 | ||
| 003 | DE-627 | ||
| 005 | 20231227131121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(23)00044-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM352833181 | ||
| 035 | |a (NLM)36773621 | ||
| 035 | |a (PII)S1473-3099(23)00044-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stafford, Adam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a A 48-year-old man with poorly controlled HIV presented with severe human monkeypox virus (hMPXV) infection, having completed 2 weeks of tecovirimat at another hospital. He had painful, ulcerating skin lesions on most of his body and oropharyngeal cavity, with subsequent Ludwig's angina requiring repeated surgical interventions. Despite commencing a second, prolonged course of tecovirimat, he did not objectively improve, and new lesions were still noted at day 24. Discussion at the UK National Health Service England High Consequence Infectious Diseases Network recommended the use of 3% topical and then intravenous cidofovir, which was given at 5 mg/kg; the patient made a noticeable improvement after the first intravenous dose. He received further intravenous doses at 7 days and 21 days after the dose and was discharged at day 52. Cidofovir is not licensed for use in treatment of hMPXV infection. Data for cidofovir use in hMPXV are restricted to studies in animals. Four other documented cases of cidofovir use against hMPXV have been reported in the USA in 2022, but we present its first use in the UK. The scarcity of studies into the use of cidofovir in this condition clearly shows the need for robust studies to assess efficacy, optimum dosage, timing, and route of administration | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cidofovir |2 NLM | |
| 650 | 7 | |a JIL713Q00N |2 NLM | |
| 650 | 7 | |a Organophosphonates |2 NLM | |
| 650 | 7 | |a Cytosine |2 NLM | |
| 650 | 7 | |a 8J337D1HZY |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Rimmer, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Gilchrist, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Kristi |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Ella P |e verfasserin |4 aut | |
| 700 | 1 | |a Waddington, Claire S |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong-James, Darius |e verfasserin |4 aut | |
| 700 | 1 | |a Swaine, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Frances |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Carlos H M |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Vagish |e verfasserin |4 aut | |
| 700 | 1 | |a ElHaddad, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Awad, Zaid |e verfasserin |4 aut | |
| 700 | 1 | |a Smart, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Mora-Peris, Borja |e verfasserin |4 aut | |
| 700 | 1 | |a Muir, David |e verfasserin |4 aut | |
| 700 | 1 | |a Randell, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Chand, Meera |e verfasserin |4 aut | |
| 700 | 1 | |a Warrell, Clare E |e verfasserin |4 aut | |
| 700 | 1 | |a Rampling, Tommy |e verfasserin |4 aut | |
| 700 | 1 | |a Cooke, Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Dhanji, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Vivienne |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Carys |e verfasserin |4 aut | |
| 700 | 1 | |a Osman, Sana |e verfasserin |4 aut | |
| 700 | 1 | |a Abbara, Aula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 23(2023), 6 vom: 10. Juni, Seite e218-e226 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:6 |g day:10 |g month:06 |g pages:e218-e226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(23)00044-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 6 |b 10 |c 06 |h e218-e226 | ||